Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Hematology/Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation

14

Pipeline Programs↗

18

Active Trials↗

13

Companies Involved↗

Hematopoietic Stem Cell Transplantation is an emerging landscape with 14 programs across 13 companies. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

81/100

Attrition Rate

8/100

Pipeline

Programs by Phase

Preclinical5

Hematopoietic Stem Cell

Talaris Therapeutics Inc.

Baracle Tab.

Seoul St. Mary's Hospital

Piperacillin-Tazobactam Combination Product

The University of Queensland

Haecs

The Second Affiliated Hospital of Chongqing Medical University

Tetanus

Robert Krance

Phase 12

Dose Extension

Institute of Hematology & Blood Diseases Hospital, China

Interleukin 2

Essen Biotech

Phase 25

Fludarabine

Sanofi

Letermovir

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

IFN-γ Positive Selected T-Cells

University Hospital, Basel, Switzerland

Melphalan

Apotex Inc.

Alemtuzumab

Genzyme, a Sanofi Company

Phase 32

Tranexamic Acid

J Molner

Cyclophosphamide IV

Assistance Publique - Hôpitaux de Paris

Approved

No programs

Analysis

Modality Breakdown

70%

Small molecule

7 of 10 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

66

clinical trials

Completed22 · 33%

Unknown status21 · 32%

Recruiting11 · 17%

Terminated5 · 8%

Not yet recruiting3 · 5%

Active, not recruiting3 · 5%

Other1 · 2%

Clinical Trials

Trial Activity

66 trials

The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06792682·15 enrolled

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

Recruiting·—·Phase 1·NCT03378102·20 enrolled

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Recruiting·UUniversity of Kansas Medical Center·Phase 1·NCT03533816·38 enrolled

Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide

Recruiting·SSamsung Medical Center·N/A·NCT06041893·20 enrolled

Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation

Recruiting·HHospices Civils de Lyon·Phase 4·NCT05743400·35 enrolled

A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT02007356·30 enrolled

A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT04547049·176 enrolled

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Recruiting·—·Phase 1·NCT06138587·15 enrolled

Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)

Recruiting·OOttawa Hospital Research Institute·Phase 3·NCT04448184·662 enrolled

CD62L Depleted Donor Lymphocyte Infusion With T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation

Recruiting·HHong Kong Children's Hospital·Phase 2·NCT06034535·23 enrolled

Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation

Recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT02161783·50 enrolled

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation

Active, not recruiting·PPediatric Transplantation & Cellular Therapy Consortium·Phase 1/2·NCT03475212·52 enrolled

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

Active, not recruiting·—·Phase 2·NCT04060277·7 enrolled

Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

Active, not recruiting·EEmory University·Phase 2·NCT04018937·43 enrolled

hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 1·NCT06444022·18 enrolled

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)